India, May 21 -- Tiziana Life Sciences Ltd. (TLSA) announced it has fully enrolled patients in its randomized, double-blind, placebo-controlled Phase 2a INFORM-MS trial evaluating intranasal Foralumab in non-active Secondary Progressive Multiple Sclerosis (na-SPMS), a form of MS characterized by gradual worsening of disability without relapses.
The study enrolled 48 patients across leading U.S. sites, testing two dose levels of intranasal Foralumab against placebo over 12 weeks, with assessments including PET imaging, MRI, clinical evaluations, and biomarkers. Following the blinded phase, all participants will be eligible for a six-month open-label extension to assess long-term safety and sustained benefit.
Topline data are expected in la...